Please assess the completion status of the following clinical trial:

Trial Title: Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of dilated cardiomyopathy~* Left ventricular ejection fraction \< 35%~* NYHA Functional classes of II-IV~* Symptomatic but not rapidly deteriorating 1 month before enrollment~* Signed informed consent~Exclusion Criteria:~* Contradictions and intolerance of the studied drugs:~  * supine systolic arterial blood pressure \< 90 mmHg,~ * renal artery stenosis \>50%,~ * pregnancy or lactation,~ * impaired renal function (estimated glomerular filtration rate \< 60 ml/min/1.73m2,~ * impaired liver function (total bilirubin \>2 times upper limit of normal,~ * serum aspartate AST or alanine ALT \>3 times the upper limit of normal),~ * hemoglobin less than 8 mg/dl, hyperkalaemia (serum potassium \>5.5mmol/l),~ * obstructive lung disease,~ * advanced atrioventricular block,~ * any co-morbidity with impact on survival, and~ * known intolerance to benazepril, valsartan and metoprolol succinate;~* HF secondary to a known cause:~  * coronary artery disease based on coronary angiography (≥50% stenosis in ≥1 of the major coronary arteries) and/or a history of myocardial infarction or angina pectoris,~ * acute or subacute stage of myocarditis,~ * primary valve disease,~ * diabetes mellitus,~ * excessive use of alcohol or illicit drugs;~* Expected or performed cardiac resynchronization therapy and heart transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Metoprolol (Type: EXPERIMENTAL): Patients in the metoprolol group were started on 11.875-23.75mg of metoprolol succinct extended-release tablet once daily (11.875mg was recommended for patients with NYHA functional classes III-IV), and then doses were doubled every 2 weeks to achieve asymptomatic bradycardia (50-60 bpm of heart rate) over 4-6 weeks. Investigators were encouraged to up-titrate metoprolol to a maximum dose of 190mg whenever possible.
- Low-dose valsartan (Type: EXPERIMENTAL): Patients randomized to low dose valsartan receive valsartan 80 mg until study completion.
- Low dose Benazepril (Type: EXPERIMENTAL): Patients randomized to low dose Benazepril receive Benazepril 10 mg until study completion.
- High dose valsartan (Type: EXPERIMENTAL): Patients randomized to high-dose valsartan were started on valsartan 80mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of valsartan is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of valsartan 320mg, 480mg, 640mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
- High dose Benazepril (Type: EXPERIMENTAL): Patients randomized to high-dose benazepril were started on benazepril 10mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of benazepril is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of benazepril 40mg, 60mg, 80mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).